The Food and Drug Administration issued a sources sought notice for small businesses capable of providing artificial intelligence analysis of non-invasive, high-resolution imaging of pharmaceutical products.
In a notice posted on SAM.gov, FDA’s Office of Pharmaceutical Quality stated that it is seeking companies for a five-year, indefinite-delivery/indefinite-quantity contract for drug imaging, which will be used in examining how product quality and performance is affected by manufacturing processes.
The agency is looking for technologies that can visually scan, analyze and measure the physical and microstructural parameters of freeze-dried and complex pharmaceuticals. According to the notice, OPQ intends to use AI technology to simulate the parameters and correlate them with product performance as well as manufacturing processes.
Vendors qualified as small businesses may submit their responses until April 19.
